ClinicalTrials.gg
CompletedNCT02001818PInNACLeUpdated Aug 6, 2024

Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

A Phase 2 interventional study of Nilotinib, Pegylated interferon alpha-2b, Imatinib in Chronic Myeloid Leukaemia, sponsored by Australasian Leukaemia and Lymphoma Group. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Australasian Leukaemia and Lymphoma Group · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
30th of 66
60 · median 55
Started
2014
with 4 others
Phase 2
25 of 66
1 open now
Registered
47th of 66
by date
Lead sponsor
1 of 66
Australasian Leukaemia and Lymphoma Group

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 30th largest by enrollment, is one of 5 that started in 2014, is one of 25 in phase 2, and was the 47th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The treatment of CML and the expected survival has been revolutionised since the introduction of tyrosine kinase inhibitors (TKIs) such as nilotinib. Despite their effectiveness, these drugs will never totally remove CML affected cells from the body. In order to achieve this goal, and potentially enable CML patients to live without the daily need for TKIs, other features of the patient's immune system may need to be harnessed. One possibility is using externally administered interferon (IFN) to augment the response induced by the TKI.

This study will assess the response in terms of length of survival, detection of minimal disease levels and time until disease worsens in patients with chronic phase CML who are taking nilotinib and pegylated Interferon. Patients will commence taking nilotinib for 3 months, and once tolerated, will simultaneously be treated with injected pegIFN for up to 2 years. Patients can continue taking nilotinib beyond this time providing they are receiving benefit. Options are available for patients to decrease or increase their dose or to switch to another TKI, imatinib, to ensure a balance between drug effectiveness and minimal side effects is achieved.

03

Conditions studied

  • Chronic Myeloid Leukaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All of the following criteria must be satisfied for enrolment in the study.

  1. Post-pubertal male or female patients aged 18 years or above.
  2. Newly diagnosed (within Three months of study entry) Ph+ CML-Chronic Phase with a quantifiable "breakpoint cluster region - Abelson murine leukemia" (BCR-ABL) transcript
  3. No prior therapy for CML and no other current anti-leukaemic therapies (other than prior or current treatment with hydroxyurea or anagrelide).
  4. No signs of extramedullary leukaemia, except for hepatosplenomegaly.
  5. Documented chronic-phase CML as defined by:

    i. \<15% blasts in both the peripheral blood and bone marrow ii. \<30% blasts and promyelocytes in both the peripheral blood and bone marrow iii. \<20% basophils in the peripheral blood iv. count >100 × 109/L (Note: Patients will be considered to be in chronic phase if their platelet count is ≤ 100 x 109/L as a result of treatment with hydroxyurea or anagrelide provided that all of the other criteria for chronic phase CML are met).

  6. Performance Status score ≤2 (see Appendix 2)
  7. Patients must have the following laboratory values:

    1. Potassium level > Lower Limit of Normal (LLN)
    2. Calcium (corrected for serum albumin) > Lower Limit of Normal (LLN)
    3. Magnesium level > Lower Limit of Normal (LLN)
    4. Phosphorus > Lower Limit of Normal (LLN)
    5. and AST \< 2.5 × or \< 5.0 × Upper limit of normal (ULN) if considered due to tumour
    6. ALP \< 2.5 × Upper limit of normal (ULN) unless considered due to tumour
    7. \< 1.5 × Upper limit of normal (ULN) unless due to Gilbert's syndrome
    8. Creatinine \< 1.5 × Upper limit of normal (ULN)
    9. Amylase and lipase \< 1.5 × Upper limit of normal (ULN) Note: Biochemical abnormalities that resolve after corrective measures pose no impediment to re-screening.

a) Female patients of must have a negative serum pregnancy test within one week prior to study entry OR have been amenorrhoeic for at least 12 months.

b) All patients of must agree to use for the duration of the study. This is only required for as long as the patient has reproductive potential. The type of birth control is a decision which should be made between the treating clinician and the patient.

9. of more than 12 months. 10.Patient has given written, to participate in the study (which includes consent to obtain samples for the correlative study except in a rare case where a site does not have the capacity to participate in the correlative study).

Exclusion criteria

Exclusion Criteria:

Presence of any of the following criteria will exclude the subject from enrolment in the study.

  1. Patients who have previously received radiotherapy to >25% of their bone marrow.
  2. Patients who have undergone major surgery within the 4 weeks prior to study entry or have not recovered from earlier surgery.
  3. Impaired cardiac function, including any of the following:

    1. Inability to monitor the /corrected QT intervak (QTc) interval on
    2. Long QT syndrome or a known family history of long QT syndrome.
    3. Resting bradycardia (\<50 beats per minute) suspected to be secondary to cardiac pathology
    4. QTc > 450 msec on baseline ECG (using the QTc formula). If QTc >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
    5. Other uncontrolled heart disease (e.g. congestive heart failure or uncontrolled hypertension)
    6. History of or presence of clinically significant ventricular or atrial tachyarrhythmias, including atrial fibrillation
  4. History of arterial vascular disease including coronary artery disease (Angina, myocardial infarction), cerebrovascular disease ( and strokes), peripheral vascular disease, retinal artery thromboses and mesenteric arterial thromboses.
  5. Treatment with agents (other than warfarin) that prolong QT interval or inhibit Cytochrome P450 3A4 (), unless judged to be clinically essential.
  6. Another primary malignant disease, except for such conditions that do not currently require treatment, lesions that can be or had been completely excised (eg Skin Cancers) and neoplasms that does not significantly affect long term survival of the patient
  7. Significantly impaired GI function or GI disease that may alter nilotinib absorption.
  8. Other concurrent uncontrolled medical conditions (e.g. uncontrolled diabetes, uncontrolled or unstable thyroid disease, active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol.
  9. History of confirmed acute or chronic pancreatitis.
  10. Cytopathologically confirmed Central Nervous System(CNS) infiltration. [In the absence of suspicion of CNS involvement, lumbar puncture is not required.]
  11. Patients unwilling or unable to comply with protocol and patients with a history of noncompliance or inability to grant .
  12. Known diagnosis of (HIV) infection.
  13. Prior stem cell transplantation
  14. Patients who are pregnant or breast feeding or adults of not employing an effective method of . Male and female patients of must agree to employ an effective method of birth control throughout the study. The type of birth control is a decision which should be made between the treating clinician and the patient
  15. Known history of uncontrolled depression or any other psychiatric disease likely to be exacerbated by study treatment. A formal psychiatric assessment at baseline is not required.
  16. Current participation in another therapeutic clinical trial (participation in clinical trials that do not involve active interventions is not an exclusion for the study.)
  17. Previous adverse reaction to the trial drug/s
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Nilotinib or Imatinib with Peginterferon

    Nilotinib 300mg twice daily for 24 months. Pegylated interferon alpha-2b 30-50 micrograms subcutaneously once weekly for maxium 21 months (3 months after trial registration). Patients intolerant of nilotinib may be switched to appropriate doses of imatinib

    Drug: Nilotinib, Pegylated interferon alpha-2b, Imatinib

Interventions

  • DrugNilotinib, Pegylated interferon alpha-2b, Imatinib

    Drug pages: NilotinibStudies of NilotinibNilotinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Peginterferon alfa-2bStudies of Peginterferon alfa-2bPeginterferon alfa-2b pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ImatinibStudies of ImatinibImatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.

06

What researchers measure

Primary outcomes

  1. level of BCR-ABL

    Time frame: 24 months of treatment

07

Study locations

1 site
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Jan 2022, 92 months.

Of 99 non-industry phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 130. This study's 92 months is above that.

Counting every sponsor, half of 124 studies reached it within 73 months; a quarter within 42 and three quarters within 121.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2013
First posted
Dec 5, 2013
StartActual
Apr 11, 2014
Primary completionActual
Jan 7, 2022
CompletionActual
Jan 7, 2022
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02001818
Lead sponsor
Australasian Leukaemia and Lymphoma Group
Responsible party
Sponsor
First posted
Dec 5, 2013
Start date
Apr 11, 2014
Primary completion
Jan 7, 2022
Completion
Jan 7, 2022
Last update
Aug 6, 2024

Study contacts

Tim Hughes, MBBS, MD, FRACP, FRCPA
principal investigator · Royal Adelaide Hospital
Andrew Grigg, MBBS, MD, FRACP, FRCPA
principal investigator · Austin Hospital, Melbourne Australia
David Yeung, BSc(Med), MBBS(Hons),FRACP
principal investigator · SA Pathology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nilotinib · Peginterferon alfa-2b · Imatinib

Start the discussion